

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Ken Shortman, et al.

**Examiner:** Scott Long

**Serial No.:** 10/584,180

**Art Unit:** 1633

**Filed:** October 11, 2006

**Docket:** 19975

**For:** THERAPEUTIC AGENTS AND  
USES THEREFOR

**Dated:** January 7, 2009

**Confirmation No.:** 4755

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143**

Sir:


In response to the Office Action dated December 10, 2008, setting forth a requirement for restriction, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, Applicants provisionally elect, with traverse, the subject matter of Group I, claims 1-12, drawn to a method for preventing the onset of an autoimmune disease in a subject comprising administering Flt-3L.

---

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: January 7, 2009

  
Xiaochun Zhu